No

Antiemetic

Treatment of nausea and vomiting associated with cancer chemotherapy

C

Nausea and vomiting not secondary to cancer chemotherapy

>10%:

Central nervous system: Dizziness, drowsiness, vertigo, euphoria, clumsiness

Gastrointestinal: Xerostomia

1% to 10%:

Cardiovascular: Orthostatic hypotension

Central nervous system: Ataxia, depression

Ocular: Blurred vision

CNS depression is potentiated with ethanol

Nabilone is a synthetic cannabinoid utilized as an antiemetic drug in the control of nausea and vomiting in patients receiving cancer chemotherapy; like delta-9-tetrahydrocannabinol (the active principal of marijuana), nabilone is a dibenzo(b,d)pyrans

Absorption: Rapid

Serum half-life: 35 hours

Oral:

<18 kg: 0.5 mg twice daily

18-30 kg: 1 mg twice daily

>30 kg: 1 mg 3 times/day

Adults: 1-2 mg twice daily beginning 1-3 hours before chemotherapy is administered and continuing around-the-clock until 1 dose after chemotherapy is completed; maximum daily dose: 6 mg divided in 3 doses

Dizziness, drowsiness, and euphoria are common; may cause depression; may rarely cause confusion and hallucinations

Concurrent use with psychotropic may produce additive sedation

No information available to require special precautions

>10% of patients experience dry mouth

May cause drowsiness, impair judgment, coordination; avoid alcohol and other CNS depressants; can cause disorientation

Capsule: 1 mg